发明授权
US09096603B2 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators
有权
1-杂环基-1,5-二氢 - 吡唑并[3,4-D]嘧啶-4-酮衍生物及其作为PDE9A调节剂的用途
![1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators](/docs/US/2015-08-04/US09096603B2/abs.jpg.600x600.jpg)
- 专利标题： 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators
- 专利标题（中）： 1-杂环基-1,5-二氢 - 吡唑并[3,4-D]嘧啶-4-酮衍生物及其作为PDE9A调节剂的用途
-
申请号： US14077534申请日： 2013-11-12
-
公开(公告)号： US09096603B2公开(公告)日： 2015-08-04
- 发明人: Riccardo Giovannini , Cornelia Dorner-Ciossek , Christian Eickmeier , Dennis Fiegen , Thomas Fox , Klaus Fuchs , Niklas Heine , Holger Rosenbrock , Gerhard Schaenzle
- 申请人： Riccardo Giovannini , Cornelia Dorner-Ciossek , Christian Eickmeier , Dennis Fiegen , Thomas Fox , Klaus Fuchs , Niklas Heine , Holger Rosenbrock , Gerhard Schaenzle
- 申请人地址： DE Ingelheim am Rhein
- 专利权人： Boehringer Ingelheim International GmbH
- 当前专利权人： Boehringer Ingelheim International GmbH
- 当前专利权人地址： DE Ingelheim am Rhein
- 代理商 Michael P. Morris; Edward S. Lazer
- 优先权： EP08153987 20080402
- 主分类号： A61K31/519
- IPC分类号： A61K31/519 ; C07D487/04
![1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators](/abs-image/US/2015/08/04/US09096603B2/abs.jpg.150x150.jpg)
摘要：
The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, wherein i.) the nitrogen atom of the pyrazolo-group that is next to the pyrimidino-group is attached to a non-aromatic, organic heterocycle having at least one ring hetero atom selected from O, N and S and ii.) to the C-atom between the two nitrogen atoms of the pyrimidinone-ring a second substituent is bound via an optionally substituted methylene-bridge. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.